Author network for Anne Kirsti Blystad by COREMINE medical

Publications 2016

Smeland KB, Kiserud CE, Lauritzsen GF, Blystad AK, Fagerli UM, Falk RS, Fluge Ø, Fosså A, Kolstad A, Loge JH, Maisenhölder M, Østenstad B, Kvaløy S, Holte H (2016)
A national study on conditional survival, excess mortality and second cancer after high dose therapy with autologous stem cell transplantation for non-Hodgkin lymphoma
Br J Haematol, 173 (3), 432-43
DOI 10.1111/bjh.13965, PubMed 26914167

Publications 2013

Bersvendsen H, Kolstad A, Blystad AK, Aurlien E, Fosså A, Kvaløy SO, Holte H, Lauritzsen GF (2013)
Multimodal treatment with ALL-like chemotherapy, Auto-SCT and radiotherapy for lymphoblastic lymphoma
Acta Oncol, 53 (5), 680-7
DOI 10.3109/0284186X.2013.855816, PubMed 24237392

Smeland KB, Kiserud CE, Lauritzsen GF, Blystad AK, Fagerli UM, Fluge Ø, Fosså A, Hammerstrøm J, Kolstad A, Loge JH, Maisenhølder M, Østenstad B, Kvaløy S, Holte H (2013)
High-dose therapy with autologous stem cell support for lymphoma in Norway 1987-2008
Tidsskr Nor Laegeforen, 133 (16), 1704-9
DOI 10.4045/tidsskr.13.0243, PubMed 24005706

Publications 2011

Fosså A, Fiskvik IH, Kolstad A, Lauritzsen GF, Aurlien E, Blystad AK, Hole KH, Ikonomou IM, Holte H (2011)
Two escalated followed by six standard BEACOPP in advanced-stage high-risk classical Hodgkin lymphoma: high cure rates but increased risk of aseptic osteonecrosis
Ann Oncol, 23 (5), 1254-9
DOI 10.1093/annonc/mdr385, PubMed 21926399

Josefsen D, Forfang L, Dyrhaug M, Blystad AK, Stokke T, Smeland EB, Kvalheim G (2011)
Side population cells in highly enriched CD34-positive cells from peripheral blood progenitor cells identify an immature subtype of hematopoietic progenitor cells but do not predict time to engraftment in patients treated with high-dose therapy
Eur J Haematol, 87 (6), 494-502
DOI 10.1111/j.1600-0609.2011.01681.x, PubMed 21752097

Publications 2004

Bilalovic N, Blystad AK, Golouh R, Nesland JM, Selak I, Trinh D, Torlakovic E (2004)
Expression of bcl-6 and CD10 protein is associated with longer overall survival and time to treatment failure in follicular lymphoma
Am J Clin Pathol, 121 (1), 34-42
DOI 10.1309/TNKL-7GDC-66R9-WPV5, PubMed 14750238

Blystad AK, Delabie J, Kvaløy S, Holte H, Vålerhaugen H, Ikonomou I, Kvalheim G (2004)
Infused CD34 cell dose, but not tumour cell content of peripheral blood progenitor cell grafts, predicts clinical outcome in patients with diffuse large B-cell lymphoma and follicular lymphoma grade 3 treated with high-dose therapy
Br J Haematol, 125 (5), 605-12
DOI 10.1111/j.1365-2141.2004.04951.x, PubMed 15147376

Smeland S, Blystad AK, Kvaløy SO, Ikonomou IM, Delabie J, Kvalheim G, Hammerstrøm J, Lauritzsen GF, Holte H (2004)
Treatment of Burkitt's/Burkitt-like lymphoma in adolescents and adults: a 20-year experience from the Norwegian Radium Hospital with the use of three successive regimens
Ann Oncol, 15 (7), 1072-8
DOI 10.1093/annonc/mdh262, PubMed 15205201

Publications 2002

Holte H, Smeland S, Blystad AK, Kvaløy S, Hammerstrøm J, Tjønnfjord GE (2002)
[Intensive chemotherapy in Burkitt's lymphoma and aggressive non-Hodgkin's lymphoma]
Tidsskr Nor Laegeforen, 122 (4), 364-9
PubMed 11915663

Publications 2001

Blystad AK, Enblad G, Kvaløy S, Berglund A, Delabie J, Holte H, Carlson K, Kvalheim G, Bengtsson M, Hagberg H (2001)
High-dose therapy with autologous stem cell transplantation in patients with peripheral T cell lymphomas
Bone Marrow Transplant, 27 (7), 711-6
DOI 10.1038/sj.bmt.1702867, PubMed 11360110

Blystad AK, Holte H, Kvaløy S, Smeland E, Delabie J, Kvalheim G (2001)
High-dose therapy in patients with Hodgkin's disease: the use of selected CD34(+) cells is as safe as unmanipulated peripheral blood progenitor cells
Bone Marrow Transplant, 28 (9), 849-57
DOI 10.1038/sj.bmt.1703244, PubMed 11781645

Blystad AK, Torlakovic E, Holte H, Kvaløy S, Lenschow E, Kvalheim G (2001)
CD34(+) cell enrichment depletes atypical CD30(+) cells from PBPC grafts in patients with HD
Cytotherapy, 3 (4), 295-305
DOI 10.1080/146532401317070934, PubMed 12171718

Williams CD, Harrison CN, Lister TA, Norton AJ, Blystad AK, Coiffier B, Taghipour G, Schmitz N, Goldstone AH, European Bone Marrow Transplant Lymphoma Working Party (2001)
High-dose therapy and autologous stem-cell support for chemosensitive transformed low-grade follicular non-Hodgkin's lymphoma: a case-matched study from the European Bone Marrow Transplant Registry
J Clin Oncol, 19 (3), 727-35
DOI 10.1200/JCO.2001.19.3.727, PubMed 11157024

Publications 1999

Josefsen D, Blomhoff HK, Lømo J, Blystad AK, Smeland EB (1999)
Retinoic acid induces apoptosis of human CD34+ hematopoietic progenitor cells: involvement of retinoic acid receptors and retinoid X receptors depends on lineage commitment of the hematopoietic progenitor cells
Exp Hematol, 27 (4), 642-53
DOI 10.1016/S0301-472X(98)00073-3, PubMed 10210322

Publications 1997

Lien HH, Blomlie V, Blystad AK, Holte H, Langholm R, Kvaløy S (1997)
Bone-marrow MR imaging before and after autologous marrow transplantation in lymphoma patients without known bone-marrow involvement
Acta Radiol, 38 (5), 896-902
PubMed 9332252

Sweetenham JW, Taghipour G, Milligan D, Blystad AK, Caballero D, Fassas A, Goldstone AH (1997)
High-dose therapy and autologous stem cell rescue for patients with Hodgkin's disease in first relapse after chemotherapy: results from the EBMT. Lymphoma Working Party of the European Group for Blood and Marrow Transplantation
Bone Marrow Transplant, 20 (9), 745-52
DOI 10.1038/sj.bmt.1700963, PubMed 9384476